| Similar Articles |
|---|
 |
The Motley Fool
May 15, 2007
Brian Lawler |
King Fights for Its Empire King Pharmaceuticals announces another good quarter of financial results. Investors should expect more product acquisitions in the coming years.   |
The Motley Fool
March 3, 2009
Robert Steyer |
Seeking Gain From Pain King Pharmaceuticals tries to remake itself as a pain therapy company. |
The Motley Fool
November 5, 2007
Brian Lawler |
King's Abuse-Resistant Bet King Pharmaceuticals signs a development deal with Acura Pharmaceuticals to produce abuse-resistant painkillers. Investors, take note. |
The Motley Fool
March 1, 2007
Brian Lawler |
King Atop Its Throne After two quarters of middling revenue growth, drugmaker King Pharmaceuticals reported blowout sales and operating cash flow for its fourth quarter. |
The Motley Fool
September 12, 2008
Brian Lawler |
King's Unstoppable Urge to Merge King Pharmaceuticals announces it has increased its offer to acquire Alpharma, and it is now taking that bid directly to the shareholders. |
The Motley Fool
November 10, 2005
W.D. Crotty |
Portfolio Pain Relief Pain Therapeutics announces a significant development deal with King Pharmaceuticals. The company's stock is the largest percentage gainer on the Nasdaq -- up 48.9%. |
The Motley Fool
May 28, 2008
Brian Lawler |
King Pays a Modest Ransom King Pharmaceuticals, a prolific acquirer of other companies' drugs, announces that it had painlessly staked its claim to yet another. |
The Motley Fool
February 27, 2004
Zeke Ashton |
King Makes a Comeback The love/hate cycle might be ready to shift again for this pharmaceutical. King Pharmaceuticals was once a beloved growth stock. Then it became an unloved drug stock suffering from intensifying competition, a poor acquisition or two, and an ongoing SEC investigation. The stock has started to come back. |
The Motley Fool
August 25, 2008
Brian Lawler |
King Triples Down King Pharmaceuticals makes a risky all-in bet on an unproven market. |
Pharmaceutical Executive
April 1, 2007
Walter Armstrong |
Make It New To fix pharma's business model, nothing less than big, bold, and risky fits the bill. Two radical new visions focus on getting back to the roots of innovation -- and letting a thousand flowers bloom. |
The Motley Fool
December 31, 2010
Brian Orelli |
How the Other Half of Pharma Lives A dive into spec pharma. |
The Motley Fool
October 29, 2004
Bill Mann |
King, Knave, or Village Idiot? Troubled King Pharmaceuticals' latest accounting woes threaten to scuttle its merger with Mylan. |
The Motley Fool
August 14, 2009
Brian Orelli |
The Real King of the Drug Pushers King Pharma is first up with a tamper-resistant morphine tablet. |
The Motley Fool
October 12, 2010
Travis Hoium |
King Pharmaceuticals Shares Popped: What You Need to Know King Pharmaceuticals shares are up nearly 40% today after it was announced the company would be purchased by Pfizer Inc. |
The Motley Fool
April 1, 2008
Brian Lawler |
A Competitive Stab at King and Pain A new, dark-horse competitor, privately held Purdue Pharma, arrives to fight King Pharma and Pain Therapeutics. |
Pharmaceutical Executive
January 1, 2009
Stan Bernard |
Pharma vs. Pharma The most successful pharmaceutical companies will be those that can transform as the industry itself transforms. |
The Motley Fool
August 14, 2008
Brian Lawler |
A Potentially Painless PDUFA Date King Pharmaceuticals and Pain Therapeutics get an appointment with the FDA. |
Pharmaceutical Executive
September 1, 2010 |
Explaining the Drug Drought Industry needs to engage in a broader public debate on ways to rekindle the innovative engine in new drug discovery and development. |
The Motley Fool
June 24, 2011
Brian Orelli |
Come on, Pfizer, Not Even a Little Hint? Remoxy is rejected, but why? |
The Motley Fool
November 13, 2006
Brian Lawler |
King Not Loving Its Shareholders King Pharmaceuticals appears to be a company with stagnating operations, trying to grow sales via licensing or acquiring new drugs, with (at best) a shaky handling of its accounting practices. Investors, take note. |
Chemistry World
April 6, 2011
Andrew Turley |
Pfizer sells capsule business for $2.4bn Investment firm Kohlberg Kravis Roberts has agreed to pay $2.4 billion in cash for the business, which it says has 'an excellent portfolio'. |
The Motley Fool
December 7, 2007
Brian Lawler |
Pain Continues as Planned Pain Therapeutics reports on a successful phase 3 trial for its lead drug Remoxy. |
The Motley Fool
June 11, 2008
Brian Lawler |
Pain and King Start the Countdown Who will win the race to get approval of an abuse-deterrent drug, Pain Therapeutics or King Pharmaceuticals? |
Chemistry World
August 23, 2012
Simon Campbell |
Protecting patients at all costs A new funding model is urgently required to deliver innovative medicines that meet the medical needs of the 21st century and contribute to economic growth. |
The Motley Fool
September 6, 2006
Brian Lawler |
Catalyst for ZymoGenetics? Trial results for a drug that controls bleeding include a favorable comparison with a similar product. Investors, take note. |
Pharmaceutical Executive
June 1, 2005
Jan Malek |
When Two Heads are Better R&D president isn't one job-it's two. By appointing COOs for R&D with broad operational mandates, biotech and pharmaceutical companies can ensure that operational issues get the attention they urgently require. |
The Motley Fool
July 20, 2006
Stephen D. Simpson |
Wyeth Wins Again Another respectable quarter and a decent pipeline make this pharmaceutical stock worth watching. |
The Motley Fool
September 9, 2004
Charly Travers |
The Case for Drug Stocks The reports of the drug industry's death are greatly exaggerated. |
Pharmaceutical Executive
May 1, 2007 |
Thoughtleader: Thomas Nagle, Strategic Pricing Group This industry consultant believes the U.S. government will soon follow Europe's lead in taking a greater hand in price negotiations, and pharma will need to be able to communicate the value that products offer. Here he discusses how pharma can meet that challenge. |
The Motley Fool
February 26, 2010
Brian Orelli |
Drug Company Cost Cuts: Careful What You Wish For Research and development is the lifeblood of future revenue. |
The Motley Fool
April 21, 2004
Ben McClure |
Discount Pharmacy With prices beaten down across the pharmaceuticals industry and the quarterly reporting season here, do any investment opportunities pop up? |
The Motley Fool
September 12, 2005
M.D. Mitchell |
Big Problems for Big Pharma Creating new drugs is never easy, but the companies that excel in three key areas are the ones for investors to watch. |
The Motley Fool
September 10, 2008
Brian Orelli |
Are Drug Companies Being Shortsighted With R&D? Cutting research and development spending could be like playing with fire for pharmaceutical companies. |
Pharmaceutical Executive
January 1, 2007
Walter Armstrong |
Forecast 2007: At Sea In times of crisis, it's harder than ever to take the long view. The healing arts may be as old as humankind, but the business of pharma is still in its infancy. |
Salon.com
February 19, 2002
Richard Blow |
The chill is gone The once-great Stephen King has been recycling his plots and characters for 20 years now. It's time he made good on his threats to retire... |
Bank Systems & Technology
August 16, 2010
Matt Gunn |
Customer-Centered Banking is the Future, Author Says Brett King discusses his book Bank 2.0 and the future of banking. |
Bio-IT World
December 10, 2002
Jim Hall |
21st Century R&D Strategy: Atlantic or Pacific? The biopharmaceutical sector is divided by two strategic perspectives. |
Pharmaceutical Executive
July 3, 2007
Walter Armstrong |
Take Me to Your Leader Turnover in the top 10 pharmas has new CEOs racing to reinvent the way their companies do business. Running a large pharmaceutical company has becoming immensely complex, and requires a broad set of management skills. Even then, a CEO may never see a beloved molecule approved for drughood. |
PC Magazine
September 21, 2004 |
Age of Empires II: The Age of Kings The king of real-time strategy games has yet to be dethroned. |
The Motley Fool
April 2, 2007
Brian Lawler |
Pain Therapeutics Pares Shares The small drugmaker announces a share buyback. |
Pharmaceutical Executive
January 1, 2007
Glass & Poli |
Forecast 2007: Connecting the Dots How do execs rank the issues facing the pharmaceutical industry? And what are the links they see between them? A new study reveals the industry's mental map of today's challenges. |
The Motley Fool
November 23, 2004
Charly Travers |
Mylan's "Three-Ring Circus" Carl Icahn is involved in the Mylan-King Pharmaceuticals so he can manipulate this situation to make money. And a lot of it. |
The Motley Fool
September 30, 2008
Brian Orelli |
Pharma, Cash, and You Pharma's been saving for a rainy day, and there's a thunderstorm outside. |
Fast Company
Pavithra Mohan |
Activision To Buy Candy Crush Creator For $5.9 Billion Activision Blizzard, the company behind video games like Call of Duty and World of Warcraft, just inked a deal to acquire King Digital Entertainment, the maker of wildly popular mobile game Candy Crush Saga. |
Chemistry World
March 25, 2015
Dennis Lendrem |
Be careful what you wish for There is a big debate right now in the pharmaceutical industry, and specifically about measuring R&D productivity. It all comes down to a choice of metrics. |
Pharmaceutical Executive
January 21, 2014
Tim Powell |
Innovation: The Moneyball Test Successful innovation now has to align with key metrics of value; can an old baseball metaphor help guide the way? |
Chemistry World
November 6, 2009
Anna Lewcock |
Loss of senior chemist throws further doubt on future of UK drugs council David Nutt has insisted he has 'right on his side' following his unceremonious dismissal as chair of the UK Home Office Advisory Council on the Misuse of Drugs. |
IEEE Spectrum
December 2005
Hira & Goldstein |
R&D 100 Automakers top the list, drug companies trim back, and telecoms continue to gut their research budgets. |
BusinessWeek
April 10, 2006
Dean Foust |
Burger King: Where's The Beef? Burger King's upcoming IPO looks lucrative.. .for the private-equity firms doing the deal. While they make even more cash, the chain's long-term debt could hit $1 billion. |
The Motley Fool
March 21, 2011
Jim Royal |
Meet the Cash Kings of Drilling Check out Transocean, the cash king of the drilling sector. |
